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UK and 5) College of Medicine, University of Garmian, Kalar, Kurdistan Region, IraqAbstractWhile many patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eventually produce neutralising antibodies,
the degree of susceptibility of previously infected individuals to reinfection by SARS-CoV-2 is currently unknown. To better understand the
impact of the immunoglobulin (IgG) level on reinfection in recovered coronavirus disease 2019 (COVID-19) patients, anti-nucleocapsid IgG
levels against SARS-CoV-2 were measured in 829 patients with a previously confirmed infection just after their recovery. Notably, 87 of these
patients had no detectable IgG concentration. While there was just one case of asymptomatic reinfection 4.5 months after the initial recovery
amongst patients with detectable anti-nucleocapsid IgG levels, 25 of the 87 patients negative for anti-nucleocapsid IgG were reinfected within
one to three months after their first infection. Therefore, patients who recover from COVID-19 with no detectable anti-nucleocapsid IgG
concentration appear to remain more susceptible to reinfection by SARS-CoV-2, with no apparent immunity. Also, although our results
suggest the chance is lower, the possibility for recovered patients with positive anti-nucleocapsid IgG findings to be reinfected similarly exists.
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E-mail: Hassan.al-bewani2@nottingham.ac.ukIntroductionCoronavirus disease 2019 (COVID-19) is an infectious disease
caused by a 2019 novel coronavirus 2019-nCoV [1], severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
which was named so given the similarity of its symptoms to
those induced by severe acute respiratory syndrome [2]. Since
the first reports of viral pneumonia of unknown origin emerged
from China in late 2019, this disease has spread across theThis is an oworld, with new cases reported daily. The clinical manifesta-
tions of COVID-19 range widely from asymptomatic to mild,
moderate and rapidly progressive severe (pneumonia) disease
that can lead to death in some individuals [3–5]. The moderate
clinical symptoms of patients with COVID-19 include fever,
dyspnoea, fatigue, dry cough, myalgia and pneumonia. In severe
cases, affected patients may experience acute respiratory fail-
ure, septic shock and organ failure that might culminate in death
[6,7].
Transmission of SARS-CoV-2 from infected people to others
is suggested based on epidemiology and clinical evidence [8,9],
with even asymptomatic infected individuals suggested of being
capable of transmitting the virus [10,11].
Infection by SARS-CoV-2 leads to a detectable immune
response, but the susceptibility of previously infected in-
dividuals to reinfection by SARS-CoV-2 is not well understood
given the brevity of the worldwide pandemic to date. Generally,New Microbe and New Infect 2021; 43: 100926
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patients [12,13]. SARS-CoV-2 has the capacity to escape innate
immune responses, which allows the pathogen to produce large
numbers of copies in primarily infected tissues, usually airway
epithelia [14]. Principally, patients who recover from infectious
diseases such as influenza A virus are usually immunised
henceforth against infection by the causative virus for a period
of time; however, reinfection by respiratory viruses is
extremely common among humans of all ages due to these
viruses’ progressive evolution through RNA genome mutations
that lead to antigenic drift and immune escape. However, the
complete mechanisms governing our susceptibility to recurrent
viral infections remain poorly understood [15,16]. Although
some studies indicate the persistence of protective immuno-
globulin IgG levels in the blood, saliva and other body fluids for
months after infection with SARS-CoV-2 [17,18], limited
numbers of case studies of patients with COVID-19 have re-
ported positive test results after the disease symptoms had
resolved and negative test results were recorded, supporting
the possibility of reinfection [19–21]. These reports included
both patients with mild disease [22,23] and others with more
severe conditions [21,24].
This study aimed to report an additional group of COVID-19
patients who were reinfected by SARS-CoV-2 and argue that
the IgG level is a potential marker of the reinfection risk.Materials and methodsStudy population
A prospective follow-up study included a group of 829 patients
admitted to Qala Hospital, Kalar, Kurdistan region, Iraq, from
the last week of May until the middle of October 2020.
Real-time reverse-transcription polymerase chain
reaction (RT-PCR) assay for the diagnosis of SARS-
CoV-2
Pharyngeal swabs were administered to extract SARS-CoV-2
RNA from each patient; then, the total RNA was extracted
using the AddPrep Viral Nucleic Acid Extraction Kit (Addbio
Inc., Daejeon, South Korea). Next, the presence of the SARS-
CoV-2 virus was detected by real-time RT-PCR amplification
of the SARS-CoV-2 open reading frame 1ab (ORF1ab) and
envelope (E) gene fragments. The amplification reactions
were carried out with 10 μL of 2X RT-PCR master mix, 5 μL
of primer/probe mix and 5 μL of template RNA for a final
volume of 20 μL using the PowerChek SARS-CoV-2 Real-time
PCR Kit (Kogenebiotech, Seoul, Korea), described previously
[25]. We followed the kit’s instructions and adopted the
following thermocycler protocol: 50°C for 30 minutes and© 2021 The Author(s). Published by Elsevier Ltd, NMNI, 43, 100926
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seconds and 60°C for one minute. Positive and negative
controls for both genes (ORF1ab, E) were used in each run
according to the kit’s instructions. When findings regarding
the two target genes (ORF1ab, E) were positive according to
specific real-time RT-PCR, a sample was defined as positive if
the viral genome was detected at the cycle threshold value
(Ct-value) of 36.7 or less (initial infection), while the Ct-value
of greater 36.7 was defined as indicating a negative test result
or recovery (i.e., the disappearance of signs and symptoms in
a previously RT-PCR positive patient). Symptomatic persons
with the second positive RT-PCR test were considered as
reinfected patients.
Enzyme-linked immunosorbent assay
A serum sample was collected from patients with a confirmed
SARS-CoV-2 RT-PCR test result just after their recovery with a
while of 12.23 ± 2.3 days (recovery time average).
The anti-nucleocapsid IgG antibody level was assessed using
a commercially available SARS-CoV-2 IgG test kit (Pishtaz Teb
Diagnostics, Tehran, Iran) targeting the IgG antibody against the
nucleocapsid (N) antigen of the SARS-CoV-2 virus. Sera were
diluted 1:101. First, 10 μL of the specimen together with 1000
μL of the sample diluent was processed in a 96-well test kit.
Then, 100 μL of each control serum (without dilution) and
diluted specimens were placed into the appropriate well, with
the first two wells chosen as blanks and the next two chosen as
negative control wells. Positive controls were used as dupli-
cates, and the other wells were used for samples. Based on the
manufacturer’s formula, the following cut-offs were applied:
1.1, positive; 0.9 to 1.1, equivocal; and less than 0.9, negative.
Ethics declarations
All methods were used in accordance with relevant guidelines
and regulations. Also, we confirmed that all experimental
protocols were approved by the ministry of health of KRG (no.
14891 on 22/12/2020) and the Ethics Licensing Committee at
Kalar Technical Institute/Sulaimani Polytechnic University (no.
02 on 01/08/2020). In addition, informed consent was obtained
from all study participants or a parent and/or legal guardian if
the individual was younger than 18 years of age.ResultsOur study found that 86 patients tested negative for IgG spe-
cific to SARS-CoV-2 after recovery among a population of 829
patients who were infected with SARS-CoV-2 for the first time.
Twenty-six patients (14 male and 12 female patients, aged
10–60 years old) were reinfected after recovery with the rate.0/).
FIG. 1. Patients with COVID-19. Among a total of 829 patients with COVID-19, 86 (13%) showed negative findings for anti-nucleocapsid IgG specific
to SARS-CoV-2. Twenty-five (2.9%) patients were reinfected during the study period, while 61 (7%) patients remained healthy. A single patient with
anti-nucleocapsid IgG positivity was reinfected (0.1 %).
NMNI Ali et al. SARS-CoV-2 reinfection in patients negative 3of 3.13%; of these, 25 patients were in the IgG-negative group,
and only one patient was IgG-positive (Fig. 1).
Just during the first week after recovery, anti-nucleocapsid IgG
antibodies against the SARS-CoV-2 were found in 96.2% of the
serum of the reinfected patients. Only one patient was reinfected,
although the anti-nucleocapsid IgG result remained positive after
recovery from COVID-19 (Table 1). Most IgG-negative patients
presentedwith just a couple of signs of COVID-19, including fever
(96%) andmyalgia (68%) and continued cough (<15% cases), while
reinfected patients suffered more signs, including fever (96%),
myalgia (88%), continuous cough (88%), anosmia and ageusia
together (72%) (Table 2). In addition, after reinfection, more than
95% of the reinfected COVID-19 seroconvert patients had been
protected as evidenced by anti-nucleocapsid IgG antibody induc-
tion. Surprisingly, there was no detectable IgG concentration in a
male patient who hadmost of the common signs and symptoms of
COVID-19 during both his first infection and reinfection. Also, an
immunocompetent male patient (no. 26 in Tables 1 and 2) showed
a serum IgG level of 5.87 s/ca against SARS-CoV-2 nucleocapsid
after recovery but was reinfected 138 days later. Interestingly, the
reinfection induced his immune system to produce IgG level by an
amount (2.08 s/ca) less than the first infection. The occurrence of
reinfection in the group ranged from26 to 138 days after recovery
from the initial infection (Table 1).This is an oDiscussionApproximately 90% of recovered COVID-19 patients pro-
duce a detectable level of IgG [25]. In our study, among 829
infected cases, 742 IgG-positive (against SARS-CoV-2 nucle-
ocapsid) recovered patients were identified. Studies demon-
strated that detection of nucleocapsid antibody against SARS-
CoV-2 is more sensitive than antibody towards spike protein
in COVID-19 patients; Burbelo et al., concluded that the
sensitivity and specificity of nucleocapsid protein antibodies
peaks to 100% in SARS-CoV-2 when compared to spike
protein antibodies that reached 91% and 100%, respectively
[26]. Similarly, Brochot et al., confirmed that the detection of
specific antibodies against SARS-CoV-2 nucleocapsid was
more sensitive than S1 or S2 subunits [27]. A study that
included 222 patients conducted by Zhang et al., concluded
that anti-nucleocapsid antibodies were detected 4 days after
onset of symptoms [28]. However, other studies suggested a
10 days incubation period for anti-nucleocapsid IgG produc-
tion [29]. Thus, the suggested enough period of time for the
immunoglobulin production in all patients was considered in
the current study. Studies indicate that the viral load plays a
crucial role in inducing the immune system to produce an© 2021 The Author(s). Published by Elsevier Ltd, NMNI, 43, 100926
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
TABLE 1. COVID-19 data of the 26 reinfected patients in this study. The average Ct value for patients with anti-nucleocapsid IgG





















1 M 22 Jul 32.44 Negative 10 89 22.43 6.7
2 F 34 Aug 31.52 Negative 17 55 19.81 10.3
3 M 27 Sep 30.12 Negative 11 26 21.52 7.3
4 F 14 Aug 29.89 Negative 10 37 16.74 9.3
5 M 48 Aug 31.77 Negative 13 55 23.26 15.5
6 F 45 Sep 35.07 Negative 9 39 17.95 10.7
7 F 41 Aug 30.01 Negative 14 42 29.43 11.3
8 M 50 Aug 33.81 Negative 12 46 11.94 10.3
9 F 55 Aug 32.36 Negative 11 53 17.12 5.35
10 F 45 Aug 34.09 Negative 13 35 21.46 11.2
11 M 49 Jul 29.98 Negative 9 76 17.44 7.22
12 F 47 Aug 33.43 Negative 9 45 22.5 11.2
13 M 41 Aug 27.71 Negative 15 34 15.65 7.4
14 M 39 Aug 30.36 Negative 14 50 20.23 12.51
15 F 42 Aug 31.22 Negative 15 42 18.27 11.5
16 M 46 Aug 34.09 Negative 12 62 16.89 7.11
17 F 41 Aug 30.33 Negative 10 49 21.33 8.37
18 M 45 Jul 31.21 Negative 13 72 20.32 5.11
19 F 37 Aug 33.87 Negative 14 40 26.11 10.3
20 M 38 Aug 28.87 Negative 12 59 29.31 6.3
21 M 43 Aug 33.31 Negative 17 42 31.11 Negative
22 M 50 Aug 29.47 Negative 13 53 19.74 9.3
23 M 26 Aug 30.82 Negative 10 49 27.12 7.25
24 F 43 Aug 29.91 Negative 13 52 16.73 6.21
25 F 24 Aug 34.55 Negative 10 54 26.17 11.9
26 M 39 May 28.03 5.87 12 138 23.12 2.08
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severity of the disease [33]. Confirming that, we found
negative anti-nucleocapsid IgG patients with lower viral load
(Ct value mean of 31.6 ± 2.1), while viral load in positive anti-
nucleocapsid IgG reinfected patients was higher (Ct value
mean of 21.3 ± 4.7). Therefore, it may be postulated that
those patients who recovered from SARS-CoV-2 infection
with IgG negativity in this study were exposed to a lesser
amount of viral antigen.
The reinfection rate in the present study was greater than
those recorded by Hall et al. [34] and Graham et al. [35].
SARS-CoV-2 genomic sequences from the reinfection cases in
the study area have not been concluded yet, which raises the
expectation of new phylogenetically distinct variants of SARS-
CoV-2 that makes them more virulent.
The degree of protective immunity conferred by prior
infection and the possibility of reinfection by SARS-CoV-2 is not
well understood [21]. This study reports that around 10% of
recovered COVID-19 patients showed no detectable anti-
nucleocapsid IgG concentration after recovery and prior to
their reinfection. A pair of studies from Hong Kong and
Ecuador have also reported SARS-CoV-2 reinfection in two
anti-nucleocapsid IgG-negative patients who previously recov-
ered from COVID-19 [22,23]. The anti-nucleocapsid IgG level
appears to be associated with the severity of the illness during
the first infection; studies have shown that patients with mild© 2021 The Author(s). Published by Elsevier Ltd, NMNI, 43, 100926
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4symptoms had no/lower antibody titers as compared with
those patients with more severe symptoms [22,33,36]. In our
study, the degree of disease severity in the reinfection period
was worse in most patients than during the first instance of
COVID-19. A similar case study was reported in a 46-year-old
male Ecuadorian patient [24]. This contradicts the findings of a
couple of case studies in which patients were asymptomatic
during their reinfection period but were symptomatic during
their first infection [22,23]. The increase in disease severity in
reinfected patients can be due to a high viral load or a change in
virus virulence, which might have facilitated reinfection [21,37].
The lack of a detectable level of IgG against SARS-CoV-2
nucleocapsid during the infection period in mild or asymp-
tomatic patients possibly makes them more susceptible to
reinfection. Therefore, in the current study, it has been
observed that the vast majority of patients who showed
detectable levels of anti-nucleocapsid IgG after COVID-19
were thus mostly protected from reinfection, although the
time period of the immunity conferred by IgG against SARS-
CoV-2 nucleocapsid has not been concluded yet [22]. Unex-
pectedly, a male patient was reinfected with COVID-19 without
inducing anti-nucleocapsid IgG production a second time, which
raises the question of possible reinfection for a third time. Also,
another male patient had detectable amounts of IgG during his
first infection and was reinfected after 138 days with no
symptoms. That may be due to a decrease in his anti-.0/).
TABLE 2. Sign and symptoms among all reinfected patients during both infection and reinfection, anosmia, ageusia; shortness of
breath, SB; dark area, positive; light area, negative
NMNI Ali et al. SARS-CoV-2 reinfection in patients negative 5nucleocapsid IgG level as time passed, as studies have suggested
neutralizing IgG levels start to decrease at six to 13 weeks after
infection resolution [33,38–42]. Mysteriously, the reinfection in
the aforementioned patient induced a low level of a detectableThis is an oserum IgG concentration, which, most likely due to the low
level of induced immunoglobulin against the virus [43,44]. This
raises questions concerning the presence of adaptive immunity
in COVID-19 reinfected patients.© 2021 The Author(s). Published by Elsevier Ltd, NMNI, 43, 100926
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
6 New Microbes and New Infections, Volume 43 Number C, --- 2021 NMNIConclusionTo conclude, a lack of anti-nucleocapsid IgG in patients who
have recovered from COVID-19 may lead some to become
infected. Anti-nucleocapsid IgG production possibly indicates
the severity of the signs and symptoms of COVID-19. Further
studies are needed to consider the efficiency and sustainability
of IgG, which are likely to play a vital role in the success of the
COVID-19 vaccine industry.Author contributionsAMA performed lab work. KMA, MHF, HMT and HMR
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